Frank Lee, Forma Therapeutics CEO
September 1, 2022 09:34 AM EDTUpdated 11:22 AM
Deals
Pharma

As No­vo Nordisk be­gins PhII sick­le cell tri­al, it snags a lat­er-stage blood dis­or­der drug in $1.1B For­ma buy

Kyle LaHucik

Senior Reporter

A few weeks af­ter of­fload­ing a can­cer drug un­der re­view at the FDA, For­ma Ther­a­peu­tics is pack­ing up the rest of its be­long­ings and head­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times